<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-60330" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Rufinamide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Humayun</surname>
            <given-names>Mohammad Junaid</given-names>
          </name>
          <aff>Vanderbilt University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wadhwa</surname>
            <given-names>Roopma</given-names>
          </name>
          <aff>South Carolina Department of Mental Health</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohammad Junaid Humayun declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Roopma Wadhwa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-60330.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Rufinamide is one of the anti-seizure drugs (ASD) used as an add-on therapy to treat seizures associated with Lennox Gastaut syndrome, and it is structurally unrelated to other traditional ASDs. This CME activity provides a brief and illustrative review of this drug's FDA-approved indications and pharmacodynamic and pharmacokinetic properties. This activity will also highlight the side effects, contraindications, and dosing regimens of this drug and will also&#x000a0;discuss the practice parameters of the American Academy of Neurology guidelines regarding the utility of this drug in clinical practice.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the common drug-drug interactions in a patient with Lennox Gastaut syndrome who starts on rufinamide therapy.</p></list-item><list-item><p>Summarize the common and serious adverse effects associated with rufinamide.</p></list-item><list-item><p>Review the pharmacodynamic and pharmacokinetic properties of rufinamide.</p></list-item><list-item><p>Explain how an interprofessional team approach to rufinamide therapy can improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=60330&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=60330">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-60330.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Rufinamide is a tri-azole derivative drug structurally unrelated to any other anti-seizure drug (ASD).<xref ref-type="bibr" rid="article-60330.r1">[1]</xref>&#x000a0;It was developed first in 2004 and later was granted an orphan drug status in October 2004, and was first marketed in Europe in January 2007. It was approved by the US FDA on November 14, 2008, for the adjunctive treatment of seizures associated with Lennox Gastaut syndrome (LGS).<xref ref-type="bibr" rid="article-60330.r2">[2]</xref>&#x000a0;Interestingly, it was the first anti-seizure medication to reach the US market&#x000a0;with a pediatric indication prior to approval for adults.</p>
        <p>FDA Indication: Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in pediatric patients one year of age and older and adults.</p>
      </sec>
      <sec id="article-60330.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Rufinamide (1-[(2,6-difluorophenyl] methyl))-1hydro-1,2,3-triazole-4 carboxamide) has a tri-azole group within its structure, which has a structural resemblance to anti-fungal and fungicidal drugs; however, rufinamide has no structural similarity to any of the anti-seizure medications.</p>
        <p>The exact mechanism of action of rufinamide is unknown. In vitro, it stabilizes the inactive state of the sodium channel, limiting the sustained bursts of high-frequency action potentials and preventing sodium channels from returning to an activated state, therefore decreasing the neuronal hyperexcitability and action potential propagation.<xref ref-type="bibr" rid="article-60330.r3">[3]</xref>&#x000a0;In this way, it modulates the activity of the sodium channel, prolonging its inactivity. Rufinamide has no effect on benzodiazepine, gamma-aminobutyric acid (GABA) receptors, or adenosine uptake and has no interactions with glutamate, adrenergic, tryptophan, histamine, and muscarinic cholinergic receptors.<xref ref-type="bibr" rid="article-60330.r2">[2]</xref></p>
      </sec>
      <sec id="article-60330.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Rufinamide is available as a suspension of 40 mg/mL.</p>
        <p>Rufinamide administration iv via twice-daily dosing. In children, it is started at 10 mg/kg/day and is gradually increased by 10 mg/kg every other day to 45 mg/kg/day or 3200 mg/day (whichever is less). In adults, the dosing regimen begins with 400 to 800 mg/day, gradually increasing by 400 to 800 mg every other day, up to a maximum of 3200 mg/day. Rufinamide is administered orally and is available in two formulations: Film-coated tablets (200 mg, 400 mg) and oral suspension (40 mg/ml). If on valproic acid, the US labeling recommends that the initial rufinamide dose be 400 mg daily (&#x0003c;10 mg/kg/day) due to the enzyme inhibition effects of valproic acid.<xref ref-type="bibr" rid="article-60330.r4">[4]</xref></p>
        <p>Rufinamide has a slow absorption (T-max 4 to 6 hours) and&#x000a0;exhibits bioavailability of up to 85%.<xref ref-type="bibr" rid="article-60330.r1">[1]</xref>&#x000a0;The bioavailability is better when taken with food. The half-life of rufinamide is 6 to 10 hours and has relatively low protein binding, 26 to 34%, and binds primarily to albumin, thus having&#x000a0;few displacement drug-drug interactions. It is metabolized via a non-CYP450 pathway by carboxylase-mediated hydrolysis in the liver into its inactive metabolite. It is primarily excreted, up to 85% from kidneys, and 2% is excreted unchanged in the urine. No dose adjustment is necessary for renal impairment.<xref ref-type="bibr" rid="article-60330.r2">[2]</xref></p>
        <p>Patients with renal impairment will require no dosing adjustments. Clinicians can give 30% of the usual dose as a post-dialysis supplement for hemodialysis patients. Peritoneal dialysis dosing is undefined. Caution is advised in patients with mild to moderate hepatic impairment; with severe impairment, the recommendation is to avoid using rufinamide.</p>
      </sec>
      <sec id="article-60330.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The common adverse effect of rufinamide includes somnolence, vomiting, headache, fatigue, dizziness, nausea, and rarely, flu-like symptoms, nasopharyngitis, rash, ataxia, and diplopia.</p>
        <p>Four less common but potentially significant adverse effects related to rufinamide are shortening QT interval, multi-organ hypersensitivity/drug reaction with eosinophilia and systemic symptoms (DRESS), leukopenia, and Stevens-Johnson syndrome.<xref ref-type="bibr" rid="article-60330.r5">[5]</xref><xref ref-type="bibr" rid="article-60330.r6">[6]</xref> Other potentially serious adverse reactions include seizures with abrupt withdrawal of the drug, suicidality, and status epilepticus.<xref ref-type="bibr" rid="article-60330.r7">[7]</xref></p>
        <p>The QT interval shortening below 300 was not observed in the studies with doses up to 7200 mg per day. There was no sign of drug-induced sudden death or ventricular arrhythmias with rufinamide. However, in patients with a history of familial short QT syndrome, rufinamide was associated with an increased risk of sudden death and ventricular arrhythmia/fibrillation. Such events tend to occur when the QT interval falls below 300 msec. Therefore, caution is also necessary with the concomitant use of rufinamide with other potential drugs that shorten the QT interval.<xref ref-type="bibr" rid="article-60330.r5">[5]</xref></p>
        <p>In the clinical trials, DRESS is most commonly seen in children less than 12 years of age; it occurred within four weeks of rufinamide initiation and resolved or improved with discontinuation of the drug. Therefore, if there is an index of suspicion of DRESS, the patient should&#x000a0;undergo evaluation, and rufinamide should be discontinued and alternative treatment initiated.</p>
      </sec>
      <sec id="article-60330.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The major contraindication to the use of rufinamide is familial short QT syndrome. As discussed above, rufinamide was associated with significant ventricular arrhythmia, including cardiac death in patients with a history of short QT syndrome. Other contraindications include hypersensitivity to the drug or any components of the formulation.</p>
        <p>Minor contraindications include concomitant use of rufinamide with other potential drugs that shorten QT interval and the presence or history of the short QT interval; therefore, the recommendation is to routinely check the QT interval in these patient populations. Other contraindications include hypersensitivity to rufinamide and/or triazole derivatives.</p>
        <p>Warnings /precautions include central nervous system (CNS) effects, including cognitive and coordination dysfunction. Therefore, caution is necessary&#x000a0;regarding participating in tasks that require mental alertness. Other warnings/precautions include multi-organ hypersensitivity reactions (like DRESS, as discussed above), dermatological reactions such as Steven Johnson syndrome (SJS), leukopenia, and suicidal ideation.</p>
        <p>Hepatic impairment: Rufinamide is not recommended for use in severe hepatic impairment; however, caution is advised in mild to moderate hepatic impairment.</p>
        <p>Rufinamide is a Pregnancy Category C drug, so clinicians need to weigh the risks vs. benefits of using rufinamide during pregnancy; it is likely to be excreted in human milk. However, there is no contraindication to breastfeeding with rufinamide use.<xref ref-type="bibr" rid="article-60330.r8">[8]</xref></p>
      </sec>
      <sec id="article-60330.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>In general, Rufinamide does not require routine ancillary monitoring except for the clinical evaluation, such as seizure frequency and duration. As with other AEDs, patients can experience behavioral changes and/or suicidal ideation and dermatological reactions, eg, rash.<xref ref-type="bibr" rid="article-60330.r9">[9]</xref></p>
        <p>There are no well-established therapeutic levels of rufinamide. In one of the clinical trials, the plasma concentration for rufinamide ranged from 4.95 to 48.15 ug/ml during the maintenance period.<xref ref-type="bibr" rid="article-60330.r10">[10]</xref></p>
        <p>In general, the drug-drug interactions with rufinamide are very limited.<xref ref-type="bibr" rid="article-60330.r1">[1]</xref>&#x000a0;The&#x000a0;primary significant adverse drug-drug interaction of rufinamide, which is clinically significant, is with valproic acid, which is an enzyme inhibitor and can significantly decrease rufinamide clearance by 60-70%, thus increasing rufinamide levels, especially in the pediatric population, thus lowering rufinamide levels, especially in the pediatric population. Other contraindicated agents for concurrent use with rufinamide include amifampridine, bupropion, and metoclopramide.<xref ref-type="bibr" rid="article-60330.r11">[11]</xref></p>
        <p>Rufinamide itself is a weak inducer of CYP3A4 iso-enzyme. Still, it has&#x000a0;few drug-drug interactions with other AEDs, which metabolize through the same enzyme system as carbamazepine oxcarbazepine, zonisamide, tiagabine, topiramate, etc. The P450 enzyme inducers (like phenytoin and phenobarbital) can decrease rufinamide levels by 25&#x000a0;to 45%. Rufinamide can render oral contraceptive pills (OCP) less effective by increasing their clearance, especially ethinyl estradiol, norethindrone, and triazolam.<xref ref-type="bibr" rid="article-60330.r12">[12]</xref></p>
      </sec>
      <sec id="article-60330.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is no specific antidote for&#x000a0;treating rufinamide toxicity. Hemodialysis can cause limited clearance of rufinamide; therefore, no specific evidence is available for a rufinamide toxicity antidote except for general maneuvers for removing unabsorbed medication (emesis, gastric lavage, airway protection, etc.).<xref ref-type="bibr" rid="article-60330.r13">[13]</xref></p>
      </sec>
      <sec id="article-60330.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Rufinamide is one of the newer generation anti-epileptic medications, which initially was granted an orphan drug status and later got FDA approval for add-on therapy for seizures associated with Lennox Gastaut syndrome in children older than &#x0003e; one year and in adults. American Academy of Neurology (AAN) published updates on practice parameters in treatment-resistant epilepsy in 2018, in which two Class I studies were reviewed.<xref ref-type="bibr" rid="article-60330.r14">[14]</xref>&#x000a0;There was a significant reduction in drop attacks, a change in median tonic-atonic seizures, median total seizure frequency, and an increase in responder rates when compared with placebo.</p>
        <p>For treatment-resistant adult focal epilepsy (TRAFE), three class I studies were reviewed by AAN, and updates on practice parameters were published in 2018.<xref ref-type="bibr" rid="article-60330.r14">[14]</xref>&#x000a0;Rufinamide demonstrated effectiveness with a reduction in median seizure frequency, &#x0003e; 50% responder rate, but benefits were modest.</p>
        <p>For the treatment of other childhood epileptic encephalopathies other than LGS, one study found rufinamide may be an effective and better-tolerated add-on therapy for the treatment of refractory childhood-onset epileptic encephalopathies other than LGS and was the most effective in patients with drop-attacks.<xref ref-type="bibr" rid="article-60330.r15">[15]</xref></p>
        <p>To conclude, rufinamide has FDA approval and is effective for add-on therapy for seizures associated with LGS in children older than 1 year and adults. It is also effective in TRAFE and potentially effective in other childhood epileptic encephalopathies other than LGS. It is generally well tolerated with minimal other AED drug-drug interactions. It is contraindicated in familial QT syndrome, and precautionary measures are necessary when using rufinamide with other drugs that prolong QT interval. Since no generic formulation is available to date, the drug is expensive and poses financial issues.</p>
        <p>When using rufinamide, employing an interprofessional healthcare team approach to therapy is prudent and beneficial. This team includes clinicians (MDs, DOs, NPs, and PAs), specialists, nursing staff, and pharmacists, all exercising open lines of communication and operating from the same patient data. When the prescribers initiate therapy, they should have a&#x000a0;complete patient history to preclude familial short QT syndrome, and it is beneficial to have the nurse review dosing and alert the patient or parents regarding potential adverse events. The pharmacists can reinforce proper dosing and administration schedules when counseling the patient and should be available to address any potential side effects, reporting these to the prescriber or nursing so remedial action can be initiated. This interprofessional team approach to care when using rufinamide (as with any therapeutic intervention) will yield improved patient outcomes and reduce adverse events and therapeutic failure. [Level 5]</p>
      </sec>
      <sec id="article-60330.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=60330&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=60330">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/60330/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=60330">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-60330.s11">
        <title>References</title>
        <ref id="article-60330.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cloyd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Critchley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fuseau</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.</article-title>
            <source>Epilepsia</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>49</volume>
            <issue>7</issue>
            <fpage>1123</fpage>
            <page-range>1123-41</page-range>
            <pub-id pub-id-type="pmid">18503564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wheless</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Vazquez</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Rufinamide: a novel broad-spectrum antiepileptic drug.</article-title>
            <source>Epilepsy Curr</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">20126329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deeks</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Rufinamide.</article-title>
            <source>CNS Drugs</source>
            <year>2006</year>
            <volume>20</volume>
            <issue>9</issue>
            <fpage>751</fpage>
            <page-range>751-60; discussion 761</page-range>
            <pub-id pub-id-type="pmid">16953653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asadi-Pooya</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Lennox-Gastaut syndrome: a comprehensive review.</article-title>
            <source>Neurol Sci</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>403</fpage>
            <page-range>403-414</page-range>
            <pub-id pub-id-type="pmid">29124439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schimpf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Veltmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Papavassiliu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rudic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>G&#x000f6;ksu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kuschyk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wolpert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Antzelevitch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ebner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Borggrefe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brandt</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide.</article-title>
            <source>Heart Rhythm</source>
            <year>2012</year>
            <month>May</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>776</fpage>
            <page-range>776-81</page-range>
            <pub-id pub-id-type="pmid">22245794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.</article-title>
            <source>Br J Pharmacol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>159</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-69</page-range>
            <pub-id pub-id-type="pmid">19563537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohtsuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yoshinaga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shirasaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takayama</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Takano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Iyoda</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial.</article-title>
            <source>Epilepsy Res</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>121</volume>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">26827266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crettenand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rossetti</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Buclin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Winterfeld</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>[Use of antiepileptic drugs during breastfeeding : What do we tell the mother?].</article-title>
            <source>Nervenarzt</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>89</volume>
            <issue>8</issue>
            <fpage>913</fpage>
            <page-range>913-921</page-range>
            <pub-id pub-id-type="pmid">29487964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamamoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Usui</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kagawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Drug Monitoring for Rufinamide in Japanese Patients With Epilepsy: Focus on Drug Interactions, Tolerability, and Clinical Effectiveness.</article-title>
            <source>Ther Drug Monit</source>
            <year>2022</year>
            <month>Aug</month>
            <day>01</day>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>585</fpage>
            <page-range>585-591</page-range>
            <pub-id pub-id-type="pmid">35213526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sachdeo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perdomo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arroyo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.</article-title>
            <source>Neurology</source>
            <year>2008</year>
            <month>May</month>
            <day>20</day>
            <volume>70</volume>
            <issue>21</issue>
            <fpage>1950</fpage>
            <page-range>1950-8</page-range>
            <pub-id pub-id-type="pmid">18401024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johannessen Landmark</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patsalos</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>Drug interactions involving the new second- and third-generation antiepileptic drugs.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>119</fpage>
            <page-range>119-40</page-range>
            <pub-id pub-id-type="pmid">20021326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaccara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs.</article-title>
            <source>Epileptic Disord</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>409</fpage>
            <page-range>409-31</page-range>
            <pub-id pub-id-type="pmid">25515681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacob</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs.</article-title>
            <source>Drugs R D</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>303</fpage>
            <page-range>303-316</page-range>
            <pub-id pub-id-type="pmid">27766590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <article-title>Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Dec</month>
            <day>11</day>
            <volume>91</volume>
            <issue>24</issue>
            <fpage>1117</fpage>
            <pub-id pub-id-type="pmid">30530563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-60330.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coppola</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grosso</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Franzoni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Veggiotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zamponi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spalice</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Habetswallner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fels</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verrotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D'Aniello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mangano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Balestri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Curatolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pascotto</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome.</article-title>
            <source>Eur J Neurol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>246</fpage>
            <page-range>246-251</page-range>
            <pub-id pub-id-type="pmid">20666837</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
